Table 1 Clinical trials of MSCs transplantation for knee OA

BM-MSCs

100 × 10⁶

12 months

Clinical symptom improvement

NCT02365142

(phase II)

[40]

Allogenic placenta-derived MSCs

0.5–0.6 × 10⁸

24 weeks

Improve symptoms of knee osteoarthritis

IRCT2015101823298N

[35]

BM-MSCs

8–9 × 10⁶

12 months

Pain alleviation and improved walking abilities

NCT00550524

[41]

BM-MSCs

40 × 10⁶

6 months

Significantly improved pain scores

NCT01504464

(phase I/II)

[42]

Infrapatellar fat pad-derived MSCs

1.89 × 10⁶

3 months

Improved joint function, pain level

–

[43]

BM-MSCs

10 or 100 × 10⁶

12 months

Improvement in pain and symptoms

NCT02123368

(phase I/II)

[44]

Umbilical cord-derived (UC) MSCs

20 × 10⁶

12 months

Alleviate symptoms of knee joint pain

NCT02580695

(phase I/II)

[45]

BM-MSCs

40.9 × 10⁶

12 months

Pain relief, cartilage regeneration

NCT01183728

(phase I/II)

[46]